These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12420115)

  • 1. Rapid enlargement of a residual craniopharyngioma during short-term growth hormone replacement.
    Hayward R
    Childs Nerv Syst; 2002 Nov; 18(11):565; author reply 566. PubMed ID: 12420115
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid enlargement of a residual craniopharyngioma during short-term growth hormone replacement.
    Caldarelli M; Borrelli P
    Childs Nerv Syst; 2002 Nov; 18(11):567. PubMed ID: 12530355
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid enlargement of a residual craniopharyngioma during short-term growth hormone replacement.
    Niu DM; Guo WY; Pan HC; Wong TT
    Childs Nerv Syst; 2002 Apr; 18(3-4):164-5. PubMed ID: 11981627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up.
    Olsson DS; Buchfelder M; Wiendieck K; Kremenevskaja N; Bengtsson BÅ; Jakobsson KE; Jarfelt M; Johannsson G; Nilsson AG
    Eur J Endocrinol; 2012 Jun; 166(6):1061-8. PubMed ID: 22457235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement.
    Chung TT; Drake WM; Evanson J; Walker D; Plowman PN; Chew SL; Grossman AB; Besser GM; Monson JP
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):274-9. PubMed ID: 16117814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypopituitarism oddities: craniopharyngiomas.
    Karavitaki N
    Horm Res; 2007; 68 Suppl 5():151-3. PubMed ID: 18174734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GH replacement does not increase the risk of recurrence in patients with craniopharyngioma.
    Karavitaki N; Warner JT; Marland A; Shine B; Ryan F; Arnold J; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2006 May; 64(5):556-60. PubMed ID: 16649976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologic Growth Hormone-Replacement Therapy and Craniopharyngioma Recurrence in Pediatric Patients: A Meta-Analysis.
    Alotaibi NM; Noormohamed N; Cote DJ; Alharthi S; Doucette J; Zaidi HA; Mekary RA; Smith TR
    World Neurosurg; 2018 Jan; 109():487-496.e1. PubMed ID: 28987837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Night sleep EEG and daytime sleep propensity in adult hypopituitary patients with growth hormone deficiency before and after six months of growth hormone replacement.
    Schneider HJ; Oertel H; Murck H; Pollmächer T; Stalla GK; Steiger A
    Psychoneuroendocrinology; 2005 Jan; 30(1):29-37. PubMed ID: 15358440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors.
    Jostel A; Mukherjee A; Hulse PA; Shalet SM
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):698-705. PubMed ID: 15943832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative ectopic craniopharyngioma. Case report.
    Ragoowansi AT; Piepgras DG
    J Neurosurg; 1991 Apr; 74(4):653-5. PubMed ID: 2002381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone therapy does not induce cancer.
    Sheppard MC
    Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):532-3. PubMed ID: 17024147
    [No Abstract]   [Full Text] [Related]  

  • 13. Replacement therapy with growth hormone and pituitary tumor recurrence: the relevance of the problem.
    Losa M; Gatti E; Rossini A; Lanzi R
    J Endocrinol Invest; 2008 Sep; 31(9 Suppl):75-8. PubMed ID: 19020392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone replacement therapy reduces risk of cancer in adult with growth hormone deficiency: A meta-analysis.
    Li Z; Zhou Q; Li Y; Fu J; Huang X; Shen L
    Oncotarget; 2016 Dec; 7(49):81862-81869. PubMed ID: 27835910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative pituitary hormonal disturbances and hormone replacement therapy time and dosage in children with craniopharyngiomas.
    Li GM; Sun XJ; Shao P
    Chin Med J (Engl); 2008 Oct; 121(20):2077-82. PubMed ID: 19080279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Growth factor substitution after radical removal of craniopharyngioma].
    Feldkamp J; Scherbaum WA
    Dtsch Med Wochenschr; 1997 Oct; 122(42):1298-9. PubMed ID: 9378068
    [No Abstract]   [Full Text] [Related]  

  • 17. Hypopituitarism: oddities.
    Shimatsu A
    Horm Res; 2007; 68 Suppl 5():137. PubMed ID: 18174731
    [No Abstract]   [Full Text] [Related]  

  • 18. Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy.
    Colao A; Di Somma C; Savanelli MC; De Leo M; Lombardi G
    Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S41-8. PubMed ID: 16690338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence.
    Arnold JR; Arnold DF; Marland A; Karavitaki N; Wass JA
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):435-8. PubMed ID: 19236640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final height and growth hormone secretion after completion of growth hormone therapy in patients with idiopathic growth hormone deficiency and with abnormalities of the hypothalamic-pituitary region.
    Hilczer M; Smyczynska J; Stawerska R; Lewinski A
    Neuro Endocrinol Lett; 2005 Feb; 26(1):19-24. PubMed ID: 15726014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.